Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CASC8
- Ownership
- Private
- Development stage
- Other
01
Overview
Casc8 is an early-stage biotechnology company focused on developing novel therapeutics that target long non-coding RNAs (lncRNAs) involved in cancer progression. The company's primary focus is on the CASC8 (Cancer Susceptibility 8) locus, which has been genetically linked to various cancers including colorectal, prostate, and breast cancer. By leveraging a proprietary platform to modulate lncRNA expression and function, Casc8 aims to disrupt oncogenic signaling pathways that are traditionally difficult to target with conventional small molecules. The company is currently in the discovery and pre-clinical validation phase for its lead programs.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeRNA therapy
- Industry
- Biotech
Beyond the preview
Go deeper on CASC8.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CASC8.